{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:22:36Z","timestamp":1775686956755,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["20061"],"award-info":[{"award-number":["20061"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","award":["RF-2021-12371961"],"award-info":[{"award-number":["RF-2021-12371961"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.breast.2026.104703","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:34:57Z","timestamp":1769560497000},"page":"104703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Epigenetic and fragment-based profiling across CDK4\/6 inhibitors in first-line HR+\/HER2\u2013 metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study"],"prefix":"10.1016","volume":"86","author":[{"given":"Claudia","family":"Noto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Foffano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Giudici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Molteni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Franzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Tessitori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Cucciniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bolzonello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Da Ros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Bortot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Scudeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenno","family":"Past\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Cudia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Della Rossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Bonotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro Marco","family":"Minisini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Damante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Belletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8313-4834","authenticated-orcid":false,"given":"Lorenzo","family":"Gerratana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104703_bib1","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib2","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013Negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib3","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-Positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104703_bib4","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104703_bib5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2021.39.15_suppl.1001","article-title":"Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+\/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) \u00b1 ribociclib (RIB)","volume":"39","author":"Slamon","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib6","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104703_bib7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in Pre- and perimenopausal patients with HR+\/HER2\u2212 advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104703_bib8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-Negative breast cancer that progressed on endocrine Therapy\u2014MONARCH 2","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.breast.2026.104703_bib10","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-GS01-12","article-title":"Abstract GS01-12: MONARCH 3: final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer","volume":"84","author":"Goetz","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104703_bib11","doi-asserted-by":"crossref","first-page":"LBA1003","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1003","volume":"40","author":"Finn","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103863","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors (CDK4\/6i): mechanisms of resistance and where to find them","volume":"79","author":"Foffano","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104703_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2407-14-59","article-title":"ESR1gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients","volume":"14","author":"Mart\u00ednez-Gal\u00e1n","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2026.104703_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-1804-1_1","author":"Kanwal","year":"2015","journal-title":"Cancer Epigenetics: An Introduction"},{"key":"10.1016\/j.breast.2026.104703_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.550185","article-title":"Plasma-based longitudinal evaluation of ESR1 epigenetic status in hormone receptor-positive HER2-Negative metastatic breast cancer","volume":"10","author":"Gerratana","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174277","article-title":"Liquid biopsy, an everchanging balance between clinical utility and emerging technologies","volume":"14","author":"Cucciniello","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104703_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693104","article-title":"Clinical and pharmacologic differences of CDK4\/6 inhibitors in breast cancer","volume":"11","author":"George","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41523-023-00520-7","article-title":"The dilemma of selecting a first line CDK4\/6 inhibitor for hormone receptor-positive\/HER2-negative metastatic breast cancer","volume":"9","author":"Grinshpun","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.breast.2026.104703_bib20","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1200\/PO.20.00345","article-title":"Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer","volume":"5","author":"Gerratana","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/1878-0261.12415","article-title":"High-throughput isolation of circulating tumor DNA: a comparison of automated platforms","volume":"13","author":"van Dessel","year":"2019","journal-title":"Mol Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/1878-0261.12037","article-title":"Application of circulating tumor DNA in prospective clinical oncology trials \u2013 standardization of preanalytical conditions","volume":"11","author":"Van Dessel","year":"2017","journal-title":"Mol Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","article-title":"The CDK4\/6 inhibitor revolution \u2014 a game-changing era for breast cancer treatment","volume":"21","author":"Morrison","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib24","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104703_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.03.023","article-title":"Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+\/HER2- BC patients: results from the multicenter PALMARES-2 study","author":"Provenzano","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.550185","article-title":"Plasma-based longitudinal evaluation of ESR1 epigenetic status in hormone receptor-positive HER2-Negative metastatic breast cancer","volume":"10","author":"Gerratana","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1 -Mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104703_bib28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102456","article-title":"Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics","volume":"59","author":"Foffano","year":"2025","journal-title":"Transl Oncol"},{"key":"10.1016\/j.breast.2026.104703_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2023.03.001","article-title":"Serum thymidine kinase activity in patients with HR-positive\/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: results from the prospective BioItaLEE trial","volume":"186","author":"Malorni","year":"2023","journal-title":"Eur J Cancer"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:30:56Z","timestamp":1775683856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":30,"alternative-id":["S0960977626000135"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104703","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic and fragment-based profiling across CDK4\/6 inhibitors in first-line HR+\/HER2\u2013 metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104703"}}